JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
